Your Good Partner in Biology Research

  1. Home
  2. 抗体
  3. 单克隆抗体
  4. LAG3 Monoclonal Antibody

LAG3 Monoclonal Antibody

  • 货号：
    CSB-MA012719A0m
  • 规格：
    ￥1320
  • 图片：
    • Western Blot
      Positive WB detected in: 1 lane: Recombinant proteins with LAG3; 2 lane: 293F whole cell lysate transfected with LAG3
      All lanes: LAG3 antibody at 1:2000
      Secondary
      Goat polyclonal to mouse IgG at 1/50000 dilution
      Predicted band size: 76, 88 KDa
      Observed band size: 76, 88 KDa
      Exposure time:5min
    • IHC image of CSB-MA012719A0m diluted at 1:500 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at 37°C Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-Mouse IgG labeled by HRP and visualized using 0.05% DAB.
    • IHC image of CSB-MA012719A0m diluted at 1:500 and staining in paraffin-embedded human appendix tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at 37°C Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-Mouse IgG labeled by HRP and visualized using 0.05% DAB.
    • Overlay Peak curve showing A549 cells stained with CSB-MA012719A0m (red line) at 1:100. The cells were incubated in 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1µg/1*106cells) for 1h at 4°C. The secondary antibody used was FITC-conjugated Goat Anti-Mouse IgG(H+L) at 1/100 dilution for 30min at 4°C. Isotype control antibody (green line) was mouse IgG1 (1µg/1*106cells) used under the same conditions. Acquisition of >10,000 events was performed.
  • 其他：

产品详情

  • 产品描述：

    The LAG3 monoclonal antibody production process involves immunizing mice with recombinant human LAG3 protein (29-450aa), then isolating B cells from the mouse spleen, fusing them with myeloma cells to produce hybridomas, and selecting and culturing hybridomas that produce LAG3 antibodies. The LAG3 monoclonal antibody is purified using protein G affinity chromatography from the mouse ascites and has a purity of over 95%. Its specificity has been tested in ELISA, WB, IHC, and FC applications.

    LAG3 protein mainly regulates immune responses by suppressing T-cell activation and promoting T-cell exhaustion. It binds to MHC class II molecules on antigen-presenting cells, leading to the inhibition of T-cell activation and the promotion of immune tolerance. LAG3 protein is being targeted as a potential immunotherapy target in cancer treatment due to its ability to regulate immune responses.

  • 产品名称：
    Mouse anti-Homo sapiens (Human) LAG3 Monoclonal antibody
  • Uniprot No.：
    P18627
  • 基因名：
  • 别名：
    CD223 antibody; CD223 antigen antibody; FDC protein antibody; LAG-3 antibody; Lag3 antibody; LAG3_HUMAN antibody; Lymphocyte activating 3 antibody; Lymphocyte activation gene 3 antibody; Lymphocyte activation gene 3 protein antibody; Protein FDC antibody
  • 宿主：
    Mouse
  • 反应种属：
    Human
  • 免疫原：
    Recombinant Human Lymphocyte activation gene 3 protein (29-450AA)
  • 免疫原种属：
    Homo sapiens (Human)
  • 标记方式：
    Non-conjugated
  • 克隆类型：
    Monoclonal
  • 抗体亚型：
    IgG1
  • 纯化方式：
    >95%, Protein G purified
  • 克隆号：
    8B12E10
  • 浓度：
    It differs from different batches. Please contact us to confirm it.
  • 保存缓冲液：
    Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
  • 产品提供形式：
    Liquid
  • 应用范围：
    ELISA, WB, IHC, FC
  • 推荐稀释比：
    Application Recommended Dilution
    WB 1:1000-1:5000
    IHC 1:200-1:1000
    FC 1:50-1:200
  • Protocols：
  • 储存条件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 货期：
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

产品评价

靶点详情

  • 功能：
    Lymphocyte activation gene 3 protein: Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as FGL1. FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function. Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1. Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells. Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function. Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation. Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear.; May function as a ligand for MHC class II (MHC-II) on antigen-presenting cells (APC), promoting APC activation/maturation and driving Th1 immune response.
  • 基因功能参考文献：
    1. Results demonstrated that the expression of LAG3 in colorectal carcinoma tissue was significantly increased compared with the paracancerous tissue. It was mainly expressed at the edge of tumor tissues suggesting that LAG3 was expressed on tumorinfiltrating lymph node cells but not in colorectal cancer cells. PMID: 30272332
    2. These results together suggested that LAG-3 is a marker of CD4(+) T cells with regulatory function; at the same time, LAG-3 might have limited the full suppressive potential of Treg cells. PMID: 29671649
    3. Among the 89 patients, CD274, LAG3, and IDO1 expressions in TIICs were observed in 68.6% (61 cases), 13.5% (12), and 28.1% (25) of patients, respectively. CD274, CTLA4, and IDO1 were expressed in tumor cells of 24.7% (22 cases), 4.5% (4), and 72.0% (64) of patients, respectively. PMID: 29520442
    4. LAG-3+ iTILs are enriched in estrogen receptor-negative breast cancers and represent an independent favorable prognostic factor. In addition, a high proportion of PD-1/PD-L1+ tumors are co-infiltrated with LAG-3+ TILs. PMID: 29045526
    5. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors. PMID: 27835902
    6. Data suggest that blocking LAG3-MHC class II interactions is a potential therapeutic target in chronic lymphocytic leukemia. PMID: 28154084
    7. LAG-3 expression was correlated with expression of PD-1 on TILs and expression of PD-L1 on tumor cells. Higher expression of LAG-3 on TILs was significantly correlated with higher expression of PD-1 on TILs and higher expression of PD-L1 on tumor cells. PMID: 28132868
    8. the upregulation of others syncytial molecules, including LAG3, CTLA4, CD28 and CD3, assisting the formation of syncytia with APC cells. PMID: 27108398
    9. LAG3-expressing CD4(+)CD25(-) T cells represent another regulatory immune cell type with potential to interfere with anti-tumor immunity. PMID: 28935468
    10. Overexpression of lymphocyte activation gene-3 inhibits regulatory T cell responses in osteoarthritis PMID: 28800255
    11. Egr2-driven cell surface proteins LAG-3 and 4-1BB can identify dysfunctional tumor antigen-specific CD8(+) TIL. PMID: 28115575
    12. our data indicate that the evaluation of stromal TILs remains the most reliable immune prognostic marker in TNBC, and support the clinical evaluation of anti-PD-1/PD-L1 and anti-LAG-3 in a subset of patients with TNBC who have concurrent expression of both checkpoint receptors. PMID: 27912781
    13. this review provides the translational rationale for targeting LAG3, as well as historical and current state of clinical trials utilizing LAG3 cancer immunomodulators PMID: 28258692
    14. this study shows that LAG3 expressed on myeloid leukaemia cells possess the capacity to facilitate functional exhaustion in T helper cells PMID: 27565576
    15. epigenetic modification on LAG-3 increased LAG-3(+) T cells and its immune regulatory roles in chronic osteomyelitis progression PMID: 28028751
    16. Immune checkpoint proteins are co-inhibitory factors that can diminish the antigen-specific immune responses by attenuating the regulatory role of cytotoxic T-lymphocyte-associated protein 4, programmed cell death-1, lymphocyte-activation gene 3, and T-cell immunoglobulin mucin-3. PMID: 28349816
    17. LAG3 binds alpha-synuclein preformed fibrils (PFF) with high affinity (dissociation constant = 77 nanomolar), whereas the alpha-syn monomer exhibited minimal binding. alpha-Syn-biotin PFF binding to LAG3 initiated alpha-syn PFF endocytosis, transmission, and toxicity. PMID: 27708076
    18. An IL-27/Lag3 axis enhances Foxp3+ regulatory T cell-suppressive function and therapeutic efficacy. PMID: 26013006
    19. LAG-3 is highly expressed in peripheral blood CD8+ T cells in chronic HBV-infected patients. PMID: 27053622
    20. iNKT cytokine production is profoundly altered by both HIV infection and treatment, and LAG-3, but not PD-1, expression is associated with a reduction in iNKT IFNgamma production. PMID: 25810006
    21. NFKB1, CD27, LAG3 and IKZF3 are new susceptibility genes for psoriasis. PMID: 25006012
    22. The elevated expression of LAG-3 at the genital tract suggests it may regulate T-cell activation, and identify cells susceptible to HIV infection. The enrichment of LAG-3 on double negative T cells suggests LAG-3 may contribute to the immunoregulatory activity of these cells. PMID: 25154740
    23. the LAG-3/MHC class II pathway may synergize with PD-1/PD ligand to enhance T cell-mediated immune responses. PMID: 25780040
    24. LAG-3 trafficking from lysosomal compartments to the cell surface is dependent on the cytoplasmic domain through protein kinase C signaling in activated T cells. PMID: 25108024
    25. These results suggest that LAG-3-mediated activation of plasmacytoid dendritic cells takes place in vivo at tumor sites, and it is in part responsible for directing an immune-suppressive environment. PMID: 24441096
    26. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. PMID: 23261718
    27. our data suggest that the LAG-3-MHC II interaction could be viewed as a bidirectional immune escape pathway in melanoma PMID: 21441454
    28. Multiple myeloma was associated with 2 SNPs in intron regions of LAG3 within 20 k base pairs 5' upstream of the candidate CD4 gene. The variant in LAG3 gene itself may play a role in susceptibility of MM. PMID: 20568250
    29. Analysis identified a gene-set (LAG3, LPL, ZAP70) whose overexpression is assigned to unmutated immunoglobulin variable heavy chain region with 90% specificity. PMID: 20228263
    30. LAG-3 defines an active CD4(+)CD25(high)Foxp3(+) regulatory T cell subset whose frequency is enhanced in the PBMCs of patients with cancer PMID: 20421648
    31. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. PMID: 20385810
    32. MHC class II-mediated signals induced by the natural ligand, LAG-3, lead to complete maturation of monocyte-derived dendritic cells, which acquire the capacity to trigger naive T cells and drive polarized Th1 responses. PMID: 11937541
    33. LAG-3 induces rapid protein phosphorylation of phospholipase Cgamma2 and p72syk as well as activation of phosphatidyl inositol 3-kinase/Akt, p42/44 extracellular signal-regulated protein kinase, and p38 mitogen-activated protein kinase pathways. PMID: 12775570
    34. LAG3 may mediate sphingolipid metabolism PMID: 12825348
    35. LAG-3 activates antigen-presenting cells through MHC class II signalling, leading to increased antigen-specific T-cell responses in vivo. PMID: 14644131
    36. regulatory T cells and LAG-3 have pivotal roles in the suppression of EBV-specific cell-mediated immunity in Hodgkin lymphoma PMID: 16757686
    37. The result, including a total of 2640 MS patients and 2194 controls shows no significant association with CD4 and LAG3 and MS. We conclude that these genes are of minor importance in regard of genetic predisposition to the MS. PMID: 17020785
    38. Soluble human recombinant fusion protein (hLAG-3Ig) used in vitro as a single maturation agent induces phenotypic maturation of monocyte-derived dendritic cells and promotes the production of chemokines and TNF-alpha inflammatory cytokine. PMID: 18322184

    显示更多

    收起更多

  • 亚细胞定位：
    [Lymphocyte activation gene 3 protein]: Cell membrane; Single-pass type I membrane protein.; [Secreted lymphocyte activation gene 3 protein]: Secreted.
  • 组织特异性：
    Primarily expressed in activated T-cells and a subset of natural killer (NK) cells.
  • 数据库链接：

    HGNC: 6476

    OMIM: 153337

    KEGG: hsa:3902

    STRING: 9606.ENSP00000203629

    UniGene: Hs.409523